Eighth Day

Eighth Day sells a tightly edited line of doctor-formulated skin-care treatments centered on its patented peptide-rich “Regenerative Plasma Serum.” The range spans cleansers, treatment serums, eye and neck creams, hydrators, and SPF, all positioned in the premium tier with single SKUs from $85 to $350. Distribution is DTC through eighthdayskin.com, augmented by selective placement in high-end dermatology clinics and luxury e-retailers such as Violet Grey and Net-a-Porter. The brand’s origin in the lab of New York plastic surgeon Dr. Antony Nakhla gives it clinical authority; every formula is bio-engineered with a proprietary blend of growth factors, amino acids, and bioidentical phospholipids designed to mimic fetal healing. Hero product The Regenerative Serum has become a cult post-procedure staple for speeding barrier recovery and boosting collagen, earning press in Vogue, Allure, and GOOP as “the injectable alternative.” Core buyers are 30-55-year-old professionals who view skin as an extension of wellness and are comfortable paying for evidence-based, medical-grade actives without a prescription. They value minimalist routines, clean clinical aesthetics, and the credibility of a surgeon founder, gravitating toward the brand’s promise of surgical-level results without downtime. Eighth Day competes in the white space between luxury cosmeceuticals and pre/post-procedure pharmaceuticals, differentiating through its patented human-adult-fibroblast-derived peptide complex that is not sold as a commodity ingredient to other brands. While competitors rely on standard growth-factor blends or high-percentage single actives, Eighth Day markets a closed-system, regeneration-focused regimen backed by surgical data, allowing it to command clinic-level prices online.